Government Regulation for more information. We may be required to suspend or discontinue clinical trials due to unexpected side effects or other safety risks that could preclude approval of our product candidates. Our clinical trials may be suspended at any time for a number of reasons. For example, we may voluntarily suspend or terminate our clinical trials if at any time we believe that they present an unacceptable risk to the clinical trial patients. In addition, the FDA or other regulatory a...
Q2 FY2026 — expected 2026-08-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001193125-26-131928 | EDGAR | 80K words |
| 2025-04-01 | 2024-12-31 | 0001641172-25-001932 | EDGAR | — |
| 2024-04-01 | 2023-12-31 | 0001493152-24-012357 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001493152-23-010332 | EDGAR | — |
| 2022-03-30 | 2021-12-31 | 0001493152-22-008080 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001493152-25-022304 | EDGAR | 28K words |
| 2025-08-14 | 2025-06-30 | 0001641172-25-024020 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001641172-25-010935 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001493152-24-045137 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001493152-24-031675 | EDGAR | — |
| 2024-05-10 | 2024-03-31 | 0001493152-24-018704 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001493152-23-040598 | EDGAR | — |
| 2023-08-16 | 2023-06-30 | 0001493152-23-029125 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001493152-23-016648 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001493152-22-031491 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001493152-22-022384 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001493152-22-013294 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-04 | 0001493152-26-035995 | EDGAR | — |
| 2026-03-30 | 0001493152-26-013653 | EDGAR | 4K words |
| 2026-03-27 | 0001493152-26-013080 | EDGAR | — |
| 2026-03-23 | 0001493152-26-012058 | EDGAR | — |
| 2026-02-06 | 0001493152-26-005437 | EDGAR | — |
| 2026-01-02 | 0001493152-26-000113 | EDGAR | — |
| 2025-11-14 | 0001493152-25-023604 | EDGAR | — |
| 2025-11-13 | 0001493152-25-022325 | EDGAR | — |
| 2025-08-14 | 0001641172-25-024147 | EDGAR | — |
| 2025-06-25 | 0001641172-25-016512 | EDGAR | — |
88 total filings indexed. 61 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001574094 |
| Ticker | RNXT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.renovorx.com |
| Listed | 2021-08-26 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/RNXT (~200 tokens, structured JSON with cryptographic provenance)